NO20081035L - Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet - Google Patents

Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet

Info

Publication number
NO20081035L
NO20081035L NO20081035A NO20081035A NO20081035L NO 20081035 L NO20081035 L NO 20081035L NO 20081035 A NO20081035 A NO 20081035A NO 20081035 A NO20081035 A NO 20081035A NO 20081035 L NO20081035 L NO 20081035L
Authority
NO
Norway
Prior art keywords
drug delivery
eye
delivery system
posterior segment
fixed tissue
Prior art date
Application number
NO20081035A
Other languages
English (en)
Inventor
Koumei Okabe
Fumitaka Tasaka
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO20081035L publication Critical patent/NO20081035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer et legemiddelleveringssystem ved ikke-invasiv administrasjon, som er fordelaktig ved legemiddeloverføring til et vev i posteriørsegmentet til øyet via et lokalt øyevev. Ved administrasjon av en fast sammensetning som innbefatter et legemiddel og en mukoadhesiv substans som har en adhesjonsstyrke på fra 200 til 1000 g i konjunktivalsekken, kan et legemiddelsleveringssystem som er svært fordelaktig når det gjelder legemiddeloverføring til et vev i posteriørsegmentet til øyet via et lokalt øyevev konstrueres.
NO20081035A 2005-07-29 2008-02-27 Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet NO20081035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005221388 2005-07-29
PCT/JP2006/314989 WO2007013590A1 (ja) 2005-07-29 2006-07-28 固形組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム

Publications (1)

Publication Number Publication Date
NO20081035L true NO20081035L (no) 2008-04-16

Family

ID=37683477

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081035A NO20081035L (no) 2005-07-29 2008-02-27 Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet

Country Status (8)

Country Link
US (1) US20090036552A1 (no)
EP (1) EP1930028A4 (no)
KR (1) KR101464003B1 (no)
CN (1) CN101232902B (no)
CA (1) CA2617040A1 (no)
NO (1) NO20081035L (no)
RU (1) RU2414193C2 (no)
WO (1) WO2007013590A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347847B (en) * 2003-08-20 2011-09-01 Santen Pharmaceutical Co Ltd Drug delivery system for sub-tenon administration of fine particles
BR112012010026B8 (pt) * 2009-10-30 2021-02-02 Aton Pharma Inc método de formação de um dispositivo de liberação ocular e dispositivo de liberação ocular
EP2512389B1 (en) * 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
KR20210006396A (ko) * 2018-05-04 2021-01-18 페넬론 홀랜드 홀딩 비.브이. 히알루로난 시각화용 시각화제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
NL188266C (nl) * 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
EP0108661A1 (en) * 1982-10-04 1984-05-16 Merck & Co. Inc. Stabilized hydroxypropyl cellulose ophthalmic inserts and process to sterilize the same
DE3486448T2 (de) * 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
US4946859A (en) * 1989-07-31 1990-08-07 Merck & Co., Inc. 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
FR2690846B1 (fr) * 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
AU680813B2 (en) * 1992-08-28 1997-08-14 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
DE69919554T2 (de) * 1998-10-02 2005-09-01 3M Innovative Properties Co., Saint Paul Systeme zur arzneistoffabgabe an schleimhäute
EP1231936A2 (en) * 1999-10-27 2002-08-21 K-Quay Enterprises, LLC Methods and compositions for treatment of keratoconus using protease inhibitors
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
DK1484054T3 (da) * 2002-02-22 2012-11-26 Santen Pharmaceutical Co Ltd Lægemiddelafgivelsessystem til subkonjunktival indgivelse af fine korn
RU2199988C1 (ru) * 2002-03-22 2003-03-10 Егоров Алексей Евгеньевич Способ введения лекарственных веществ при лечении заболеваний заднего отрезка глаза
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
JP2004196787A (ja) * 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
WO2004084963A1 (en) * 2003-03-25 2004-10-07 Smith & Nephew, Plc Porous medical adhesive comprising cyanonacrylate
TWI347847B (en) * 2003-08-20 2011-09-01 Santen Pharmaceutical Co Ltd Drug delivery system for sub-tenon administration of fine particles
EP1867334A4 (en) * 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND

Also Published As

Publication number Publication date
EP1930028A4 (en) 2010-11-17
EP1930028A1 (en) 2008-06-11
RU2008107696A (ru) 2009-09-10
RU2414193C2 (ru) 2011-03-20
KR20080033285A (ko) 2008-04-16
US20090036552A1 (en) 2009-02-05
CA2617040A1 (en) 2007-02-01
KR101464003B1 (ko) 2014-11-20
CN101232902B (zh) 2013-04-17
CN101232902A (zh) 2008-07-30
WO2007013590A1 (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
NO20081593L (no) Depotsammensetning
NO20083104L (no) Fast preparat
NO20081035L (no) Ikke-invasivt legemiddel-leveringssystem som anvender en fast sammensetning pa vevet i bakre segment av oyet
MY167123A (en) Conveniently implantable sustained release drug compositions
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
BRPI0410721A (pt) composições farmacêuticas espumáveis e métodos para tratamento de um distúrbio
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
WO2011127064A3 (en) Sustained-release reservoir implants for intracameral drug delivery
WO2009075859A3 (en) Formulation of insulinotropic peptide conjugates
DK1817065T3 (da) Viskoelastiske opløsninger indeholdende natriumhyaluronat og hydroxypropylmethylcellulose
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
MX2009010778A (es) Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
PL2197456T3 (pl) Kompozycje oftalmiczne na bazie polisacharydu z nasion tamaryndowca i kwasu hialuronowego
MY157790A (en) Trazodone composition for once a day administration
DE60202278D1 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
NO20065271L (no) Sammensetninger innbefattende alfa-2-delta ligander
NO20074850L (no) Oftalmologiske sammensetninger og anvendelse derav
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
WO2009032843A3 (en) Deuterated ethambutols and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application